The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring
Open accessAbstract
Voriconazole is a first-line agent in the treatment of many invasive fungal infections and is known to display highly variable pharmacokinetics. Previous studies of voriconazole therapeutic drug monitoring (TDM) have suggested concentration monitoring to be clinically useful but have been limited by small patient samples at a single institution. This multicenter retrospective study aimed to investigate relationships between voriconazole concentration and clinical outcomes and adverse events and to assess clinical factors and drug interactions that may affect voriconazole concentration. Medical records were reviewed for patients who received voriconazole and had at least 1 concentration measured at seven hospitals in Australia. The study included 201 patients with 783 voriconazole trough concentrations. Voriconazole concentrations of <1.7 mg/liter were associated with a significantly greater incidence of treatment failure (19/74 patients [26%]) than concentrations of ≥1.7 mg/liter (6/89 patients [7%]) ( P < 0.01). Neurotoxic adverse events (visual and auditory hallucinations) occurred more frequently at voriconazole concentrations of >5 mg/liter (10/31 patients [32%]) than at concentrations of ≤5 mg/liter (2/170 patients [1.2%]) ( P < 0.01). Multiple regression analysis of voriconazole concentration identified associations between increasing patient weight, oral administration of voriconazole, and coadministration of phenytoin or rifampin and significantly reduced concentrations, and associations between increasing patient age and coadministration of proton pump inhibitors and increased concentrations. Coadministration of glucocorticoids was found to significantly reduce voriconazole concentrations, inferring a previously unreported drug interaction between glucocorticoids and voriconazole.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Pascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J., & Marchetti, O. (2008) · Clinical Infectious Diseases · doi:10.1086/524669 · Cited by 887
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Czock, D., Keller, F., Rasche, F. M., & H??ussler, U. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00003 · Cited by 886 · cited 3×
“All treatment patients (n 163) 19/74 (26) 6/89 (7) 0.”
BackgroundVoriconazole: A New Triazole Antifungal Agent
Johnson, L. B., & Kauffman, C. A. (2003) · Clinical Infectious Diseases · doi:10.1086/367933 · Cited by 785
Li, X.-Q., Andersson, T. B., Ahlström, M., & Weidolf, L. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.8.821 · Cited by 644
Antifungal therapeutic drug monitoring: established and emerging indications
Andes, D., Pascual, A., & Marchetti, O. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00705-08 · Cited by 490
Pharmacokinetic/Pharmacodynamic Profile of Voriconazole
Theuretzbacher, U., Ihle, F., & Derendorf, H. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645070-00002 · Cited by 475
Pharmacokinetic/Pharmacodynamic Profile of Posaconazole
Li, Y., Theuretzbacher, U., Clancy, C. J., Nguyen, M. H., & Derendorf, H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11319340-000000000-00000 · Cited by 450
Voriconazole therapeutic drug monitoring
Smith, J., Safdar, N., Knasinski, V., Simmons, W., Bhavnani, S. M., Ambrose, P. G., & Andes, D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1570-1572.2006 · Cited by 399
Tan, K., Brayshaw, N., Tomaszewski, K., Troke, P., & Wood, N. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005283837 · Cited by 256
Andes, D., Marchillo, K., Stamstad, T., & Conklin, R. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3165-3169.2003 · Cited by 231 · cited 4×
“(32) 34 (1) Treatment 2 6 Smith et al.”
BackgroundResultInfluentialTrifilio, S., Singhal, S., Williams, S., Frankfurt, O., Gordon, L., Evens, A., Winter, J., Tallman, M., Pi, J., & Mehta, J. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705754 · Cited by 229
Troke, P. F., Hockey, H. P., & Hope, W. W. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01083-10 · Cited by 218
Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors
Blume, H., Donath, F., Warnke, A., & Schug, B. S. (2006) · Drug Safety · doi:10.2165/00002018-200629090-00002 · Cited by 216
Voriconazole Pharmacokinetics and Pharmacodynamics in Children
Neely, M., Rushing, T., Kovacs, A., Jelliffe, R., & Hoffman, J. (2010) · Clinical Infectious Diseases · doi:10.1086/648679 · Cited by 214
Weiss, J., ten Hoevel, M. M., Burhenne, J., Walter‐Sack, I., Hoffmann, M. M., Rengelshausen, J., Haefeli, W. E., & Mikus, G. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008327537 · Cited by 208
Trifilio, S., Pennick, G., Pi, J., Zook, J., Golf, M., Kaniecki, K., Singhal, S., Williams, S., Winter, J., Tallman, M., et al. (2007) · Cancer · doi:10.1002/cncr.22568 · Cited by 199
Scholz, I., Oberwittler, H., Riedel, K., Burhenne, J., Weiss, J., Haefeli, W. E., & Mikus, G. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03534.x · Cited by 184
Adverse Reactions to Voriconazole
Boyd, A. E., Modi, S., Howard, S. J., Moore, C. B., Keevil, B. G., & Denning, D. W. (2004) · Clinical Infectious Diseases · doi:10.1086/424662 · Cited by 182
Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients
Trifilio, S., Ortiz, R., Pennick, G., Verma, A., Pi, J., Stosor, V, Zembower, T., & Mehta, J. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704828 · Cited by 180
Voriconazole concentrations and outcome of invasive fungal infections
Miyakis, S., van Hal, S. J., Ray, J., & Marriott, D. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02990.x · Cited by 159
Self-citationNeurological adverse events to voriconazole: evidence for therapeutic drug monitoring
Imhof, A., Schaer, D. J., Schwarz, U., & Schanz, U. (2006) · Swiss Medical Weekly · doi:10.4414/smw.2006.11547 · Cited by 154
Receptor‐Based Pharmacokinetic‐Pharmacodynamic Analysis of Corticosteroids
Derendorf, H., Hochhaus, G., Mölimann, H., Barth, J., Krieg, M., Tunn, S., & Mölimann, C. (1993) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1993.tb03930.x · Cited by 136
Ueda, K., Nannya, Y., Kumano, K., Hangaishi, A., Takahashi, T., Imai, Y., & Kurokawa, M. (2009) · International Journal of Hematology · doi:10.1007/s12185-009-0296-3 · Cited by 131
Mitsani, D., Nguyen, M. H., Shields, R. K., Toyoda, Y., Kwak, E. J., Silveira, F. P., Pilewski, J. M., Crespo, M. M., Bermudez, C. A., Bhama, J. K., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05219-11 · Cited by 130
Population Pharmacokinetics of Voriconazole in Adults
Hope, W. W. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00702-11 · Cited by 116
Effect of omeprazole on the steady‐state pharmacokinetics of voriconazole
Wood, N., Tan, K., Purkins, L., Layton, G. R., Hamlin, J., Kleinermans, D., & Nichols, D. J. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.02000.x · Cited by 104
Mavridou, E., Brüggemann, R. J. M., Melchers, W. J. G., Verweij, P. E., & Mouton, J. W. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00606-10 · Cited by 96
Chhun, S., Rey, E., Tran, A., Lortholary, O., Pons, G., & Jullien, V. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2007.01.021 · Cited by 91
110 Neurological adverse events to voriconazole: Evidence for therapeutic drug monitoring
Imhof, A., Schaer, D. J., Schneemann, M., Laffer, R., & Schanz, U. (2006) · International Journal of Infectious Diseases · doi:10.1016/s1201-9712(06)80107-4 · Cited by 46
Cited by
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
Ashbee, H. R., Barnes, R. A., Johnson, E. M., Richardson, M. D., Gorton, R., & Hope, W. W. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt508 · Cited by 716
Verweij, P. E., Rijnders, B. J. A., Brüggemann, R. J. M., Azoulay, E., Bassetti, M., Blot, S., Calandra, T., Clancy, C. J., Cornely, O. A., Chiller, T., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06091-6 · Cited by 459
Metadata
- Authors
- Dolton, M. J., Ray, J. E., Chen, S. C.-A., Ng, K., Pont, L. G., & McLachlan, A. J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2012-09
- Volume
- 56
- Issue
- 9
- Pages
- 4793-4799
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2036323185
- Cited by
- 290
- References
- 31
- FWCI
- 13.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.